Blogs / Sun Pharma Share Pri...

Sun Pharma Share Price Target 2025, 2026, 2027, 2030

2026-06-19 · 3 min read

Sector - Finance

Sun Pharmaceutical Industries Ltd is not just India’s largest pharma company by market value.

Sun Pharma Share Price Target

It is one of the few Indian healthcare businesses that has successfully moved from being a domestic formulations player to a serious global pharmaceutical company.

Financial table for Sun Pharma

Market Cap₹ 4,41,082 Cr.(As of June 2026)

Price to Earnings35.4

Return on equity16.0%

Debt to equity0.06

Current ratio2.82

Dividend Yield0.87%

Return on assets12.5%

ROCE20.5%

Face Value₹1.00

52 Week High₹1,917

52 Week Low₹1,547

Sun Pharma Shareholding Pattern

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Promoters	54.69%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%
FIIs	12.81%	11.67%	14.44%	16.88%	17.72%	17.96%	15.94%
DIIs	19.56%	21.62%	20.02%	19.18%	18.71%	18.58%	21.00%
Government	0.00%	0.00%	0.00%	0.06%	0.11%	0.11%	0.11%
Public	12.94%	12.23%	11.06%	9.38%	8.97%	8.86%	8.48%
No. of Shareholders	6,31,219	7,09,045	6,62,384	6,25,252	6,31,392	7,04,983	6,90,957

Sun Pharma Price Target 2026, 2027, 2028 to 2030

YEAR 2026

Target Range (₹) : 1900-2000

for the move FY26 revenue and specialty business continued growing strongly. Projected Targets:

YEAR 2027

Target Range (₹) :

for the move Entry into top-tier global women's-health market. Projected Targets:

YEAR 2028

Target Range (₹) : 2500-3000

for the move Organon deal expected to become EPS accretive. Projected Targets:

YEAR 2029

Target Range (₹) : 2500-2700

for the move Regulatory risks across multiple jurisdictions. Projected Targets:

YEAR 2030

Target Range (₹) : 3000-3500

for the move Continued expansion beyond traditional generics.

Historic Performance:

Sun Pharma Share Price Target 2020, 2021, 2022, 2023, 2024 & 2025

YEAR 2020

Yearly returns : 37%

Start of the year price432.95

End of the year price592.35

Reason : India business remained resilient despite COVID.

YEAR 2021

Yearly returns :

Start of the year price592

End of the year price845

Reason : Specialty medicines became a larger contributor to profits.

YEAR 2022

Yearly returns :

Start of the year price845

End of the year price1001

Reason : Strengthened dermatology and specialty-drug pipeline.

YEAR 2023

Yearly returns : 29.37%

Start of the year price1001

End of the year price1295

Reason : FDA approvals and specialty-drug launches supported growth.

YEAR 2024

Yearly returns : 45.64%

Start of the year price1295

End of the year price1886

Reason : Continued strong performance in India formulations and specialty drugs.

YEAR 2025

Yearly returns : 8.29

Start of the year price1889

End of the year price1719

Reason : The U.S. regulatory environment remained challenging.

Conclusion

Sun Pharma remains one of the strongest pharma companies in India. It has scale, brand strength, global reach, healthy margins, strong India formulations, improving specialty medicine contribution and a solid long-term growth path.

FAQs

Get Stock Report

You can now get your detailed stock report

To read the RA disclaimer, please click here